

## **PBTC-025 - A SUMMARY FOR PATIENTS AND FAMILIES**

### **Title: A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449**

This is a brief summary of a clinical trial, a type of therapeutic research study. Clinical trials include only patients who choose, or whose parents permit them, to take part in the research study. Participation is entirely voluntary.

### **WHO MIGHT BE ELIGIBLE TO PARTICIPATE IN PBTC-025?**

Children who are older than 3 and less than 21 years of age, who have been diagnosed and treated previously for medulloblastoma (including posterior fossa PNET) may be eligible. Patients must have already received standard therapy, refused standard therapy or have no other standard therapy options available at this time. Eligible patients' medulloblastoma tumors have either been unresponsive to prior treatment or have re-grown after prior treatment. Patients' medical and neurological condition must be also stable at the time they begin to participate in the trial. Patients who are not eligible are those who are pregnant or breast-feeding or taking enzyme-inducing anticonvulsant (anti-seizure) medication.

Patients will need medical tests to assess whether they can participate in PBTC-025. These tests may include a medical history, physical examination, blood and urine tests and scans (MRI) of the brain and spine. Other tests may be required if doctors believe they are necessary. About 18 children from all over the U.S. will take part in PBTC-025.

### **WHY IS PBTC-025 BEING DONE?**

PBTC-025 tests a new anticancer drug called GDC-0449 in children with recurrent or treatment resistant malignant medulloblastoma tumors. This new drug interferes with a biological pathway (Sonic Hedge Hog or SHH) known to affect the growth of many cancers. For medulloblastoma, animal studies show that GDC-0449 blocks the growth of the tumor. It is not yet known how children with medulloblastomas will respond to GDC-0449.

Specifically, PBTC-025 will find out

- What daily dose of GDC-0449 may be best for further study of the drug in patients with medulloblastomas;
- What effects (good or bad) may occur when patients take GDC-0449;
- How the body processes GDC-0449;
- The levels of certain cells and proteins in the blood to see if changes are related to how the brain tumor responds to GDC-0449.

Doctors and researchers are testing GDC-0449 in children in the hopes that it will be a more effective treatment for pediatric CNS tumors than currently available therapies.

### **WHAT IS INVOLVED IN THIS STUDY?**

GDC-0449 comes in a hard gelatin capsule. Participants will need to swallow one capsule every day for 28 days. Each 28-day period (one "course") will be repeated every 4 weeks. Patients will receive up to 13 courses (or 52 weeks) of therapy.

A study participant will need scans of the brain and spine and other routine medical tests at specified times in the study. Doctors will need to take small amounts of blood to determine the safety of GDC-0449 and how it affects the medulloblastoma. They will also ask if they can study brain tumor tissue, only if it is already available, and cerebral spinal fluid, only if a child already has an Ommaya reservoir. In addition, a participant will receive a scan of the right knee and a routine dental evaluation at the start of the study and at other times during the trial. All of these studies will help doctors and researchers understand medulloblastomas as well as how GDC-0449 affects the tumor and the body.

### **WHAT ARE THE RISKS OF PARTICIPATING IN PBTC-025?**

Doctors watch study participants very carefully for any side effects or other problems. However, doctors do not know all the side effects which may occur. Side effects may be mild or very serious. In some cases, side effects may be long lasting or may never go away. There also is a risk of death. Many side effects may go away soon after a child stops taking the GDC-0449. Some of the side effects of GDC-0449 have been stomach and intestinal problems, such as nausea and vomiting, weight and hair loss, joint pain and problems in the growth of bone and teeth.

There may be unknown risks and discomforts involved in participating in this or any clinical trial. The health care team may give participants medicines to help lessen side effects. Doctors will notify parents and patients immediately of any important information or treatment findings discovered during the study that may affect their willingness to continue to participate.

### **QUESTIONS ABOUT PBTC-025?**

If you would like more information, please contact the [PBTC member institution](#) closest to you. You can also contact the doctor in charge of this study:

***Amar Gajjar, MD***  
St. Jude Children's Research Hospital  
262 Danny Thomas Place  
Memphis, TN 38105  
TEL: (901) 595-4599  
FAX: (901) 521-9005  
E-MAIL: [amar.gajjar@stjude.org](mailto:amar.gajjar@stjude.org)

### **OTHER INFORMATION IS AVAILABLE THROUGH**

The National Cancer Institute's Cancer Information Service at 1-800-422-6237 or TTY: 1-800-332-8615 or through the National Cancer Institute's websites:

[cancer.gov](http://cancer.gov)  
[CancerTrials](#): comprehensive clinical trial information  
[CancerNet](#): accurate cancer information